TAIPEI, Taiwan--(BUSINESS WIRE)--REGiMMUNE Limited (REGiMMUNE), a biotech company focused on creating innovative immunotherapies for immune disorders and cancer, and San Fu Biotech (SFB), a subsidiary of San Fu Chemical Co., Ltd. (4755.TW) have entered a licensing agreement to develop and commercialize RGI-2001 for the prophylaxis of acute Graft-versus-host disease (aGvHD) in major Asian countries.
REGiMMUNE Presented Positive Results of RGI-2001 in the Reduction of Acute GvHD from Phase 2b Study at the 2022 ASH Annual Meeting
REGiMMUNE’s lead candidate to prevent graft-versus-host disease after stem cell transplants has passed its phase 2 trial, setting the Taiwan-based biotech up for a late-stage test.